Figure 7.

AOH1996 synergizes with cisplatin to enhance cytotoxicity in cervical cancer cells. A, Dose–response matrix of AOH1996 and cisplatin combinations in HFKs, HeLa, and CaSki cells measured by MTT viability assay. Heatmaps show normalized cell viability after 96 hours of treatment. Green indicates reduced viability, and red indicates higher survival. B, Synergy contour maps generated from matrix data in A, analyzed using SynergyFinder 3.0. A synergy score >10 indicates synergy, and <−10 indicates antagonism. C, AOH1996 and cisplatin were strongly synergistic in HeLa, CaSki, and HFK 16E6E7 cells antagonistic in HFKs. Table denotes absolute synergy scores. D, Flow cytometry histogram of HeLa cells treated with 1 μmol/L AOH1996 followed by 1 μmol/L cisplatin at indicated time points. Increased sub-G1 peak at 72 and 96 hours indicates enhanced cell death. E, Quantification of cell cycle profiles confirms that AOH1996 pretreatment followed by cisplatin induces a G2/M arrest at 48 hours and a progressive increase in the sub-G1 population at 72 and 96 hours, consistent with apoptotic cell death. Bar graphs show the mean ± SEM from three independent experiments. Statistical analysis was performed using two-way ANOVA. ****, P < 0.0001.